Alirocumab for treatment of high cholesterol: effectiveness and value : new evidence update
- Collection:
- Health Policy and Services Research
- Author(s):
- Tice, Jeffrey A., author Chapman, Rick M., author Rind, David M., author Pearson, Steven D., author Kazi, Dhruv S., author Coxson, Pamela G., author Penko, Joanne, author Bibbins-Domingo, Kristen, author
- Contributor(s):
- Institute for Clinical and Economic Review, issuing body.
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, February 15, 2019
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Hypercholesterolemia -- drug therapy Proprotein Convertase 9 United States
- Genre(s):
- Technical Report
- Abstract:
- ICER’s New Evidence Update for alirocumab (Praluent®, Regeneron/Sanofi) is based on results from the ODYSSEY outcomes trial published in the New England Journal of Medicine on November 7, 2018. We used the results published in the manuscript to update our preliminary cost-effectiveness analyses and associated value-based price benchmarks for this drug. ICER’s value-based price benchmarks suggest a price range that would align fairly with the added benefits of new treatment options for patients and the health care system. ICER previously assessed the cost-effectiveness of alirocumab and evolocumab (Repatha®, Amgen Inc.) shortly after these drugs were first granted regulatory approval in the United States in 2015, and performed a New Evidence Update for evolocumab in September 2017 following the release of outcomes data from the FOURIER trial. A preliminary new evidence update for alirocumab was published on March 10, 2018, following presentation of the results at the American College of Cardiology’s 2018 Scientific Session.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (12 pages))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918401083006676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918401083006676